Revive Therapeutics (TSE:RVV) has released an update.
Revive Therapeutics Ltd. has announced positive feedback from the FDA regarding the development of Bucillamine, a drug with anti-inflammatory and antiviral properties, as a potential treatment for Long COVID. The FDA has advised the company to file a new IND application for Bucillamine, using data from their Phase 3 trial on mild to moderate COVID-19, to support their upcoming clinical trial for Long COVID. This comes as the company leverages previous research and aims to address the estimated 7.5% of U.S. adults suffering from Long COVID symptoms.
For further insights into TSE:RVV stock, check out TipRanks’ Stock Analysis page.
